A detailed history of Trust CO Of Vermont transactions in Biogen Inc. stock. As of the latest transaction made, Trust CO Of Vermont holds 1,069 shares of BIIB stock, worth $185,781. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,069
Previous 1,069 -0.0%
Holding current value
$185,781
Previous $247,000 16.19%
% of portfolio
0.01%
Previous 0.01%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 09, 2024

SELL
$190.52 - $236.72 $212,620 - $264,179
-1,116 Reduced 51.08%
1,069 $247,000
Q1 2024

May 03, 2024

SELL
$212.02 - $267.71 $1,908 - $2,409
-9 Reduced 0.41%
2,185 $471,000
Q4 2023

Mar 08, 2024

SELL
$222.59 - $267.94 $16,471 - $19,827
-74 Reduced 3.26%
2,194 $567,000
Q3 2023

Nov 27, 2023

BUY
$253.3 - $285.89 $3,039 - $3,430
12 Added 0.53%
2,268 $582,000
Q2 2023

Jul 17, 2023

SELL
$275.25 - $318.06 $550 - $636
-2 Reduced 0.09%
2,256 $642,000
Q1 2023

Apr 07, 2023

BUY
$256.56 - $292.34 $9,492 - $10,816
37 Added 1.67%
2,258 $627,000
Q4 2022

Feb 09, 2023

BUY
$252.44 - $306.72 $4,039 - $4,907
16 Added 0.73%
2,221 $615,000
Q3 2022

Oct 24, 2022

SELL
$194.69 - $268.46 $194 - $268
-1 Reduced 0.05%
2,205 $589,000
Q2 2022

Jul 20, 2022

SELL
$187.54 - $223.02 $2,062 - $2,453
-11 Reduced 0.5%
2,206 $450,000
Q1 2022

Apr 05, 2022

SELL
$193.77 - $244.14 $2,712 - $3,417
-14 Reduced 0.63%
2,217 $467,000
Q4 2021

Jan 21, 2022

SELL
$223.92 - $287.77 $27,094 - $34,820
-121 Reduced 5.14%
2,231 $535,000
Q3 2021

Oct 22, 2021

SELL
$282.99 - $369.05 $25,186 - $32,845
-89 Reduced 3.65%
2,352 $665,000
Q2 2021

Jul 15, 2021

BUY
$259.0 - $414.71 $197,358 - $316,009
762 Added 45.38%
2,441 $845,000
Q1 2021

Apr 16, 2021

SELL
$242.95 - $284.63 $17,735 - $20,777
-73 Reduced 4.17%
1,679 $470,000
Q4 2020

Feb 03, 2021

SELL
$236.26 - $355.63 $181,920 - $273,835
-770 Reduced 30.53%
1,752 $429,000
Q3 2020

Nov 06, 2020

BUY
$264.77 - $305.71 $8,207 - $9,477
31 Added 1.24%
2,522 $716,000
Q2 2020

Jul 17, 2020

SELL
$258.66 - $342.55 $64,665 - $85,637
-250 Reduced 9.12%
2,491 $666,000
Q1 2020

Apr 24, 2020

BUY
$268.85 - $341.04 $19,357 - $24,554
72 Added 2.7%
2,741 $867,000
Q4 2019

Feb 06, 2020

BUY
$220.06 - $304.07 $8,142 - $11,250
37 Added 1.41%
2,669 $792,000
Q3 2019

Oct 24, 2019

SELL
$217.44 - $243.88 $36,312 - $40,727
-167 Reduced 5.97%
2,632 $613,000
Q2 2019

Jul 26, 2019

SELL
$219.29 - $241.72 $47,147 - $51,969
-215 Reduced 7.13%
2,799 $654,000
Q1 2019

May 01, 2019

BUY
$216.71 - $338.96 $866 - $1,355
4 Added 0.13%
3,014 $712,000
Q4 2018

Jan 30, 2019

SELL
$278.5 - $352.75 $8,912 - $11,288
-32 Reduced 1.05%
3,010 $906,000
Q3 2018

Oct 26, 2018

SELL
$293.51 - $383.83 $39,623 - $51,817
-135 Reduced 4.25%
3,042 $1.08 Million
Q2 2018

Jul 11, 2018

BUY
$257.52 - $306.91 $11,588 - $13,810
45 Added 1.44%
3,177 $922,000
Q1 2018

May 18, 2018

SELL
$260.13 - $367.91 $19,249 - $27,225
-74 Reduced 2.31%
3,132 $857,000
Q4 2017

Feb 02, 2018

BUY
$307.64 - $344.58 $7,691 - $8,614
25 Added 0.79%
3,206 $1.02 Million
Q3 2017

Oct 24, 2017

BUY
$281.15 - $329.69 $894,338 - $1.05 Million
3,181
3,181 $996,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $25B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Trust CO Of Vermont Portfolio

Follow Trust CO Of Vermont and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Trust CO Of Vermont, based on Form 13F filings with the SEC.

News

Stay updated on Trust CO Of Vermont with notifications on news.